CFM-2

CFM-2 is a potent and selective non-competitive AMPAR antagonist[1]. CFM-2 possesses anticonvulsant activity in various models of seizures[2].

Product Specifications

CAS Number

[178616-26-7]

UNSPSC

12352005

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Cancer-Kinase/protease

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/CFM-2.html

Purity

98.93

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C1NN=C(C2=CC=C(N)C=C2)C3=CC(OC)=C(OC)C=C3C1

Molecular Formula

C17H17N3O3

Molecular Weight

311.34

References & Citations

[1]De Sarro G, et al. Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. Eur J Pharmacol. 1999 Mar 5;368 (2-3) :149-59.|[2]Rizzo M, et al. Determination of new 2,3-benzodiazepines in rat plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1999 Aug 20;731 (2) :207-15.|[3]Stepulak A, et al. AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther. 2007 Dec;6 (12) :1908-15.|[4]Park JS, et al. Role of spinal cord alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in complete Freund's adjuvant-induced inflammatory pain. Mol Pain. 2008 Dec 30;4:67.